OCCURENCE OF FREE AMINO ACIDS — VERTEBRATES 413 
FREE AMINO ACIDS IN THE BLOOD OF MAN AND ANIMALS 
V. EFFECTS OF MYLERAN, DIMETHYLMYLERAN, AND 
RELATED COMPOUNDS IN CHRONIC GRANULOCYTIC LEUKEMIA 
GEORGE ROUSER, KEITH KELLY, BOHDAN JELINEK 
AND DOROTHY HELLER 
Departments of Biochemistry and Medicine, City of Hope Medical Center, 
Duarte, Calif (U.S.A.) 
The previous parts of this series describe the methods for the chromatographic 
studies, the results with untreated patients, and the effects of nitrogen mustard and 
other drugs on free amino acid levels. The effects of the myleran series of compounds 
in patients with chronic granulocytic leukemia are presented here. 
GENERAL METHODS OF STUDY 
Five patients with chronic granulocytic leukemia were studied as indicated in Table IT. 
Each patient was studied for several weeks prior to receiving any form of treatment. 
During the pretreatment period glutamine ingestion studies were carried out (see 
part VI). A sixth patient with chronic lymphatic leukemia was studied in a similar 
manner to provide information on the differences in response of the chronic leukemias 
to drugs. The body weights given in Table II are indicative only of the general size 


TABLE II 
roe . Pre- Initial Months : 2 ,  Lotal 
Patient Sex Age i or Diae  iveat- — WBC| of DMM tap EB, A oane ioc 
2 dosts ment mm study neg Malet: sambles 
R. Tho. 3 56 E57 Cale. mone | 147,000 2.5 I 14 
M. Fal. ¢ 14 LOOM Cai Gam ayes 87 000 8 2 19 
D, Fol. g 44 tog C.G. none 135 000 2.5 I I 17 
H. Gol. 3 2 Lo5p CG Mone §40010008 16 4 65 
R. Tap. 3 47 i750 Ca Ge none. 1371000) les 2 I I 28 
@F aur 3 28 Lue  CuGe none  OS1000)8 il I I I IO 
Total 10 2 3 I 153 

Fairly typical differential counts were: R. Tho., polymorphonuclear neutrophils 6%, lympho- 
cytes 93°, monocytes 1%; M. Fal., polymorphonuclear neutrophils 25°, metamyelocytes 
17%, myelocytes 30%, blasts 7%, basophils 21%; D. Fol., polymorphonuclear neutrophils 
23%, metamyelocytes 49%, myelocytes 6%, lymphocytes 4%, monocytes 3%, promyelocytes 
10%, eosinophils 1%, blasts 4°; H.Gol., polymorphonuclear neutrophils 30°, metamye- 
locytes 36%, myelocytes 17°, lymphocytes 3°, promyelocytes 6%, eosinophils 3°%, basophils 
5%; RK. Tap. polymorphonuclear neutrophils 48%, metamyelocytes 32%, myelocytes 12%, 
lymphocytes 5%; basophils 3°; Q. Tur., polymorphonuclear neutrophils 30%, metamyelocytes 
37%, myelocytes 23%, lymphocytes 7%, eosinophils 3 %. 
* Myleran, 9 series of treatments up to 3 months before the amino acid studies. DMM = 
dimethylmyleran, M = myleran, CB 2432 = an isomer of dimethylmyleran. 
References p. 447/448 
